Information about Lurasidone
Lurasidone is a second generation (atypical) antipsychotic agent that is used in the treatment of schizophrenia.
Liver safety of Lurasidone
Lurasidone is associated with a low rate of serum aminotransferase elevations during therapy, but has not been linked to instances of clinically apparent acute liver injury.
Mechanism of action of Lurasidone
Lurasidone (loo ras' i done) is a second generation antipsychotic agent which appears to act as a dopamine type 2 (D2) and serotonin (5-HT)-2A receptor antagonist in a manner similar to risperidone.
FDA approval information for Lurasidone
Several randomized controlled trials have shown that lurasidone improves symptoms of schizophrenia and it was approved for this indication and for depressive episodes associated with bipolar disorder in the United States in 2010. Lurasidone is available as tablets of 20, 40, 80 and 120 mg under the brand name Latuda.
Dosage and administration for Lurasidone
The typical maintenance dose in adults is 80 to 160 mg daily.
Side effects of Lurasidone
Common side effects include somnolence, fatigue, restlessness (akathisia), anxiety, headache, dizziness, constipation, increased appetite, weight gain, orthostatic hypotension and nasopharyngitis. Rare, but potential severe adverse reactions (mentioned in most antipsychotic and antidepressant product labels) include tardive dyskinesia, major neurologic events, neuroleptic malignant syndrome, orthostatic hypotension, seizures, neutropenia, elevations in serum prolactin levels, and suicidal thoughts and behaviors.
Second Generation (Atypicals)
- Aripiprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Iloperidone, Lurasidone, Olanzapine, Paliperidone, Pimavanserin, Quetiapine, Risperidone, Ziprasidone